Pharmacists on the Front Lines of Myelofibrosis Care: Addressing Symptom Burden, Treatment Complexity, and Access Challenges

In this Pharmacy Times Q&A, Addie Planas, PharmD, CPh, CSP, discusses the complex and often unpredictable treatment journey for patients with myelofibrosis and the critical role pharmacists play in optimizing care. She highlights how ambulatory pharmacists help manage significant symptom burden, monitor for cytopenias and treatment-related adverse effects, and support adherence through frequent patient touchpoints. Planas also explains how treatment selection among Janus kinase (JAK) inhibitors is guided by individual patient factors such as anemia status and prior therapy response. Beyond clinical management, pharmacists help patients navigate high-cost specialty therapies by facilitating prior authorizations, financial assistance programs, and insurance coordination. As new targeted and combination therapies emerge, Planas emphasizes that pharmacists will become increasingly central to treatment decision-making, safety monitoring, and improving patient quality of life.

Pharmacy Times: From your perspective as an ambulatory clinical specialist, what are the most significant challenges patients with myelofibrosis face throughout their treatment journey, and how can pharmacists help address them?

Addie Planas, PharmD, CPh, CSP: Patients with myelofibrosis experience a long, complex, and often unpredictable treatment journey. Because this disease is chronic and is often managed with oral oncolytics, pharmacists play a critical role in disease optimization. One of the most significant challenges patients face is a high symptom burden and a quality-of-life impact seen most often at diagnosis. Patients commonly experience severe fatigue, night sweats, bone pain, and early satiety from splenomegaly or weight loss. Pharmacists can detect subtle decline during routine reassessment calls to patients and can assist in management and earlier referral to providers. Cytopenias are another common challenge patients with myelofibrosis face throughout their treatment journey. Pharmacists can assist by monitoring complete blood count [CBC] trends closely and recommending dose modifications to physicians. The cost of oral oncolytic therapy is another challenge for myelofibrosis patients. Patients may experience high co-pays, prior authorization delays, and treatment interruption due to insurance changes. Pharmacists can assist patients with manufacturer assistance programs and grants and by expediting the prior authorization process. Ambulatory pharmacists can also provide regular reassessment touchpoints with patients that encourage symptom discussion, adherence, and emotional support. Ambulatory pharmacists impact both clinical outcomes and quality of life.

Pharmacy Times: With the expanding landscape of JAK inhibitors and emerging therapies, how do you approach treatment selection and sequencing for patients with myelofibrosis in real-world practice?

Planas: Treatment selection for myelofibrosis patients starts with identifying the dominant problem and setting a treatment goal. Primary issues can vary from symptom burden, massive splenomegaly, anemia/transfusion dependence, or loss of prior JAK inhibitor response. The frontline JAK inhibitor landscape includes ruxolitinib [Jakafi; Incyte; Novartis], fedratinib [Inrebic; Celgene], or momelotinib [Ojjaara; GSK]. In real-world practice, anemia status drives the frontline decision. If a patient has platelets over 100,000/µL and does not have severe anemia, ruxolitinib is the best front-line option. If a patient has significant anemia or is transfusion dependent, momelotinib should be considered. If ruxolitinib is contraindicated or a patient is ruxolitinib intolerant, fedratinib is a reasonable alternative. Second-line or post–JAK failure strategy options include switching to an alternative JAK inhibitor, investigational combination approaches, or referral to a clinical trial.

Pharmacy Times: What role do pharmacists play in monitoring and managing treatment-related adverse effects, such as cytopenias, infections, or gastrointestinal symptoms, in patients receiving myelofibrosis therapies?

Planas: Pharmacists contribute to the safe and effective use of myelofibrosis therapies because most patients are on long-term oral agents that require proactive monitoring. Early pharmacist interventions frequently prevent dose interruptions, hospitalization, or premature discontinuation. Cytopenia management poses the greatest challenge, as it may be a feature of the disease or [an adverse] effect of drug therapy. Distinguishing the cause is crucial to management. Pharmacists monitor CBC trends (not just single values), identify platelet decline or worsening anemia, and assist with anemia management as part of ongoing monitoring of patients on myelofibrosis therapies. Pharmacists counsel patients prior to treatment initiation and recommend updating immunizations and advise how to detect early signs of infection. During refill questionnaire calls, infection patterns can be identified early before they escalate. Pharmacists also provide proactive strategies during initial counseling of new therapies that include taking with food when appropriate, hydration guidance, and tips to avoid gastrointestinal [adverse] effects, as well as how to manage these [adverse] effects if they do occur. Gastrointestinal symptoms can be manageable with proactive counseling and will reduce the need for early discontinuation. Pharmacists play an essential role in anticipatory management of [adverse] effects and the ongoing monitoring of myelofibrosis patients.

Pharmacy Times: How can pharmacists support medication adherence and persistence in this population, particularly given the chronic nature of myelofibrosis and the complexity of treatment regimens?

Planas: Pharmacists are one of the most influential health care providers that impact adherence and persistence. Ambulatory pharmacists can provide a thorough oral chemotherapy education before the start of a new medication. This education can be verbal, as well as printed, and can include tips to promote adherence, like setting alarms, strategies for missed doses, and recommendations for [adverse] effect management. Pharmacists can also set expectations, explaining that symptom improvement may take several weeks. Scheduling an early follow-up call for new medications allows for early and proactive [adverse] effect management. Frequent touchpoints with patients can build accountability and establish a trusted relationship with the pharmacist. Scheduling refill reminder calls well before they are due also helps improve adherence. Identifying financial burdens early can also improve persistence and adherence. Pharmacists can enroll patients in co-pay assistance programs and expedite prior authorizations to prevent gaps in therapy or prevent refill delays. These strategies improve adherence, premature discontinuation of medications, and patient confidence.

Pharmacy Times: Access and affordability remain major concerns for many patients with rare hematologic malignancies. How do you help patients navigate insurance coverage, prior authorizations, and financial assistance programs for myelofibrosis treatments?

Planas: Most myelofibrosis therapies are high-cost, specialty-distributed medications. The first step involves a full benefit investigation and a prior authorization. Ensuring proper documentation of diagnosis, prior treatments, and lab values are submitted in accordance with guideline-based therapy allows for timely approvals. If denied, ambulatory pharmacists can draft appeal letters with supporting documentation and rationale for therapy. For commercially insured patients with high co-pays, applying manufacturer co-pay cards can reduce co-payments. Actively looking for grants available to myelofibrosis patients when eligible can also be an excellent source to reduce co-pays. For patients who are uninsured or underinsured, pharmacists can coordinate enrollment into patient assistance programs. Many specialty pharmacies have teams that will work together with the pharmacists to track application status and ensure patients receive their medications. Once patients have prior authorizations or patient assistance programs in place, pharmacists can assist with renewing these programs before they expire to prevent gaps in therapy. Ambulatory pharmacists have a unique position to bridge the clinical and operational aspects of myelofibrosis treatment.

Pharmacy Times: Looking ahead, how do you see the role of ambulatory care pharmacists evolving as new targeted and disease-modifying therapies for myelofibrosis continue to emerge?

Planas: The role of ambulatory pharmacists will expand as the landscape evolves from symptom-directed JAK inhibitor therapy to targeted and possible combination therapy. As newer agents emerge, pharmacists will play a larger role in interpreting clinical data and supporting therapeutic decisions. As combination therapy becomes more common, complexity in management increases. Pharmacists will become central to dose modification recommendations and drug-drug interaction management. If newer therapies remain chronic, persistence and adherence become even more critical. Pharmacist touchpoints will continue to offer value to the patient population. Ambulatory pharmacists are uniquely positioned to provide real-world feedback from patients and to collaborate with prescribers and industry partners. As the complexity of myelofibrosis therapies emerges, the value of ambulatory pharmacists is increased.